Ani Pharmaceuticals (ANIP) Total Debt (2010 - 2026)

Ani Pharmaceuticals has disclosed Total Debt across 17 years of filings, most recently posting $301.5 million for Q2 2026.

• In Q2 2026, Total Debt fell 4.2% year-over-year to $301.5 million; the TTM figure through Jun 2026 stood at $301.5 million (down 4.2% YoY), while the FY2025 annual figure was $309.1 million, down 2.88% from the prior year.
• Total Debt came in at $301.5 million for Q2 2026 at Ani Pharmaceuticals, down from $305.3 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $320.1 million in Q3 2024 to a low of $285.2 million in Q2 2024.
• Average Total Debt over 5 years is $302.3 million, with a median of $306.8 million recorded in 2023.
• Year-over-year, Total Debt soared 56.55% in 2022 and slipped 8.07% in 2024.
• Over 5 years, Total Debt stood at $286.5 million in 2022, then rose by 3.69% to $297.1 million in 2023, then climbed by 7.13% to $318.3 million in 2024, then declined by 2.88% to $309.1 million in 2025, then retreated by 2.47% to $301.5 million in 2026.
• Per Business Quant data, the three most recent Total Debt figures were $301.5 million in Q2 2026, $305.3 million in Q1 2026, and $309.1 million in Q4 2025.